Active Not Recruiting PHASE2 INTERVENTIONAL 1-arm NCT04703686

Treatment by a Bispecific CD3xCD20 Antibody for Relapse/Refractory Lymphomas After CAR T-cells Therapy

A Phase II Trial Evaluating Glofitamab, a Bispecific CD3xCD20 Antibody for Relapse/Refractory Lymphomas After CAR T-cells Therapy

Sponsor: The Lymphoma Academic Research Organisation

Conditions Diffuse Large B-Cell Lymphoma Refractory Refractory Indolent Adult Non-Hodgkin Lymphoma Refractory Mantle Cell Lymphoma Refractory Primary Mediastinal Large B-Cell Cell Lymphoma Refractory Transformed B-cell Non-Hodgkin Lymphoma

Interventions Obinutuzumab RO7082859

Updated 11 times since 2021 Last updated: Jan 23, 2025 Started: Mar 30, 2021 Primary completion: Jan 10, 2023 Completion: Mar 1, 2026

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE2 clinical study on Diffuse Large B-Cell Lymphoma Refractory and Refractory Indolent Adult Non-Hodgkin Lymphoma, this trial is ongoing. The trial is conducted by The Lymphoma Academic Research Organisation and has accumulated 11 data snapshots since 2021. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.

Status Flow

Change History

11 versions recorded

Sep 2025 — Present [monthly]

Active Not Recruiting PHASE2
Feb 2025 — Sep 2025 [monthly]

Active Not Recruiting PHASE2
Sep 2024 — Feb 2025 [monthly]

Active Not Recruiting PHASE2
Jul 2024 — Sep 2024 [monthly]

Active Not Recruiting PHASE2
Jan 2024 — Jul 2024 [monthly]

Active Not Recruiting PHASE2

▶ Show 6 earlier versions

Oct 2023 — Jan 2024 [monthly]

Active Not Recruiting PHASE2

Status: Recruiting → Active Not Recruiting
Feb 2023 — Oct 2023 [monthly]

Recruiting PHASE2
Sep 2022 — Feb 2023 [monthly]

Recruiting PHASE2
Sep 2021 — Sep 2022 [monthly]

Recruiting PHASE2
May 2021 — Sep 2021 [monthly]

Recruiting PHASE2

Status: Not Yet Recruiting → Recruiting
Feb 2021 — May 2021 [monthly]

Not Yet Recruiting PHASE2

First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

The Lymphoma Academic Research Organisation

Data source: The Lymphoma Academic Research Organisation

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Clermont-Ferrand, France , Créteil, France , Dijon, France , Lille, France , Montpellier, France , Nantes, France , Paris, France , Pessac, France , Pierre-Bénite, France , Rennes, France and 3 more locations